• Inovio reports positive data from Phase II Covid-19 DNA vaccine trial pharmaceutical-technology
    May 12, 2021
    The Inovio vaccine Phase II trial assessed the safety, tolerability and immunogenicity of two doses of INO-4800 to detect optimal dose(s) for age groups, namely 18 to 50 years and 51 years and above, for the Phase III efficacy analysis.
PharmaSources Customer Service